14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
VTGN vs MTNB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Vistagen Therapeutics, Inc. (VTGN) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VTGN carries a Unified Composite Score of 42.3/100 (HOLD) at $0.19 (N/M Forward P/E, -2543.1% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. VTGN 42.3/100 HOLD), VTGN captures the overall institutional head-to-head verdict (3–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-2543.1% vs. 0.0% operating margin) and revenue trajectory (-46.5% vs. -100.0% YoY).
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VTGN vs MTNB Key Questions & Quantitative Answers
As of Nov 19, 2026, Vistagen Therapeutics, Inc. (VTGN) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VTGN carries a Unified Composite Score of 42.3/100 (HOLD) at $0.19 (N/M Forward P/E, -2543.1% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. VTGN 42.3/100 HOLD), VTGN captures the overall institutional head-to-head verdict (3–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-2543.1% vs. 0.0% operating margin) and revenue trajectory (-46.5% vs. -100.0% YoY).
VTGN leads the Growth & Scale pillar: VTGN posts -46.5% YoY revenue growth and +0.0% YoY earnings growth on $2.4M TTM revenue (100.0% gross margin, -2543.1% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), VTGN cumulative revenue shifted N/A while MTNB shifted N/A. In operating R&D and SG&A reinvestment, VTGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.
VTGN and MTNB trade at balanced relative valuation multiples. VTGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTGN (-144.9% ROE) versus MTNB (-147.5% ROE) capital efficiency.
In options market volatility and institutional positioning, VTGN carries 274.8% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 80% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.